Trials / Completed
CompletedNCT06181045
A Study of LY3410738 in Healthy Adult Participants
A Phase 1, Single-Ascending-Dose, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3410738 in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to assess the safety and tolerability of LY3410738 and to look at the amount of the study drug, LY3410738, that gets into the blood stream and how long it takes the body to get rid of it when given in healthy adult participants. For each participant, the total duration of the study will be 53 days, including screening.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3410738 | Administered orally. |
| DRUG | Placebo | Administered orally. |
Timeline
- Start date
- 2021-02-24
- Primary completion
- 2021-08-04
- Completion
- 2021-08-04
- First posted
- 2023-12-26
- Last updated
- 2023-12-26
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06181045. Inclusion in this directory is not an endorsement.